Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1989 May;52(5):559–565. doi: 10.1136/jnnp.52.5.559

Randomised double blind controlled trial of cyclosporin in multiple sclerosis.

P Rudge 1, J C Koetsier 1, J Mertin 1, J O Mispelblom Beyer 1, H K Van Walbeek 1, R Clifford Jones 1, J Harrison 1, K Robinson 1, B Mellein 1, T Poole 1, et al.
PMCID: PMC1032160  PMID: 2659736

Abstract

In a 2 year double blind controlled trial of cyclosporin against placebo in multiple sclerosis conducted at two centres there was a beneficial effect of the therapy upon the progression of the disease, relapse rate and relapse severity at one of the centres where the patients received a mean dose of 7.2 mg/kg/day. This beneficial effect was not seen in the other centre where a lower dose (mean 5 mg/kg/day) was given. Reduction in clinical progression was accompanied by decreased IgG synthesis in the central nervous system. Side effects included hypertension, renal insufficiency and anaemia and were of such severity to preclude the use of cyclosporin in a high enough dose to alter the course of the disease.

Full text

PDF
559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti S., Boraschi D., Luini W., Tagliabue A. Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. Int J Immunopharmacol. 1981;3(4):357–364. doi: 10.1016/0192-0561(81)90031-x. [DOI] [PubMed] [Google Scholar]
  2. Bolton C., Borel J. F., Cuzner M. L., Davison A. N., Turner A. M. Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J Neurol Sci. 1982 Nov;56(2-3):147–153. doi: 10.1016/0022-510x(82)90138-1. [DOI] [PubMed] [Google Scholar]
  3. Bunjes D., Hardt C., Röllinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981 Aug;11(8):657–661. doi: 10.1002/eji.1830110812. [DOI] [PubMed] [Google Scholar]
  4. Calder V. L., Bellamy A. S., Owen S., Lewis C., Rudge P., Davison A. N., Feldmann M. Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients. Clin Exp Immunol. 1987 Dec;70(3):570–577. [PMC free article] [PubMed] [Google Scholar]
  5. Chisholm P. M., Drayson M. T., Cox J. H., Ford W. L. The effects of cyclosporin on lymphocyte activation in a systemic graft-vs.-host reaction. Eur J Immunol. 1985 Oct;15(10):1054–1059. doi: 10.1002/eji.1830151018. [DOI] [PubMed] [Google Scholar]
  6. Feurer C., Chow L. H., Borel J. F. Preventive and therapeutic effects of cyclosporin and valine2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Immunology. 1988 Feb;63(2):219–223. [PMC free article] [PubMed] [Google Scholar]
  7. Gonsette R. E., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol. 1977 Feb 17;214(3):173–181. doi: 10.1007/BF00316148. [DOI] [PubMed] [Google Scholar]
  8. Halliday A. M., McDonald W. I., Mushin J. Visual evoked response in diagnosis of multiple sclerosis. Br Med J. 1973 Dec 15;4(5893):661–664. doi: 10.1136/bmj.4.5893.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  10. KURTZKE J. F. FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS. Neurology. 1965 Jul;15:654–661. doi: 10.1212/wnl.15.7.654. [DOI] [PubMed] [Google Scholar]
  11. Kappos L., Patzold U., Dommasch D., Poser S., Haas J., Krauseneck P., Malin J. P., Fierz W., Graffenried B. U., Gugerli U. S. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study. Ann Neurol. 1988 Jan;23(1):56–63. doi: 10.1002/ana.410230110. [DOI] [PubMed] [Google Scholar]
  12. Link H., Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest. 1977 Sep;37(5):397–401. doi: 10.1080/00365517709091498. [DOI] [PubMed] [Google Scholar]
  13. Mertin J., Rudge P., Kremer M., Healey M. J., Knight S. C., Compston A., Batchelor J. R., Thompson E. J., Halliday A. M., Denman M. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet. 1982 Aug 14;2(8294):351–354. doi: 10.1016/s0140-6736(82)90547-5. [DOI] [PubMed] [Google Scholar]
  14. Patzold U., Hecker H., Pocklington P. Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients. J Neurol Sci. 1982 Jun;54(3):377–394. doi: 10.1016/0022-510x(82)90201-5. [DOI] [PubMed] [Google Scholar]
  15. Polman C. H., Koetsier J. C., Wolters E. C. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clin Neurol Neurosurg. 1985;87(3):187–192. doi: 10.1016/0303-8467(85)90005-8. [DOI] [PubMed] [Google Scholar]
  16. Rumjanek V. M., Smith L. A., Morley J. Modulation by cyclosporin-A of mononuclear cell distribution during experimental allergic encephalomyelitis. Int J Immunopharmacol. 1984;6(2):99–104. doi: 10.1016/0192-0561(84)90003-1. [DOI] [PubMed] [Google Scholar]
  17. Sheikh K., Smith D. S., Meade T. W., Brennan P. J., Ide L. Assessment of motor function in studies of chronic disability. Rheumatol Rehabil. 1980 May;19(2):83–90. doi: 10.1093/rheumatology/19.2.83. [DOI] [PubMed] [Google Scholar]
  18. Suckling A. J., Baron P. W., Reiber H. Chronic relapsing experimental allergic encephalomyelitis: cyclosporin-A treatment of relapsing and remitting disease. J Clin Lab Immunol. 1986 Dec;21(4):173–176. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES